NanoViricide, Inc., presents research on anti-Ebola agents

The results of NanoViricide, Inc.’s research into anti-Ebola agents were presented on July 17 to the Annual Meeting of the American Society for Virology at Montana State University in Bozeman, Montana.

The studies, dubbed “Polymeric Micelle Nanomaterials as Antiviral Compounds for Ebola Virus Infection," were performed at the United States Army Medical Research Institute of Infectious Diseases in Frederick, Maryland, and were presented by Dr. Corinne Scully.

In cell culture screenings, the nanoviricides demonstrated a dose dependent inhibition of the Ebola virus’s infectivity that showed no toxicity of uninfected cells at concentrations that were effective against virus infected cells, according to

Some of the nanoviricides that were effective in cell culture studies were used for testing in vivo in a mouse model of Ebola infection. The compounds were well tolerated by the animals and showed some efficacy against the mouse-adapted Ebola, as demonstrated in the increased lifespan of the mice. The animal model was, however, 100 percent lethal.

The results of this study are expected to help guide the creation of the next-generation of anti-Ebola nanoviricides. Those that are optimized will be studied for their effects against similar hemorrhagic fever viruses, including the Marburg virus.

Based on the results of this study, and its previous success against the Dengue fever virus, NanoViricides, Inc., believes that it can develop a single drug that is effective against both the Marburg and Ebola filoviruses. Currently, there is no treatment for either.